Iannello Silvai, Milazzo Paolina, Bordonaro Fabio, Belfiore Francesco
Department of Medicina Interna e Patologie Sistemiche, University of Catania Medical School, Garibaldi Hospital, Catania, Italy.
MedGenMed. 2006 Dec 20;8(4):60.
Hypertrophic scars and keloids are 2 forms of excessive cutaneous scarring that occur in predisposed individuals. The healing process varies greatly among patients, and the risk of a bad scar evolution is unpredictable. Keloids create disfiguring scars with associated erythema and pain or pruritus or restricted range of motion, and are a major cause of morbidity. A fortuitous observation was made by the first author of this study who, at age 54, developed an erythematous and painful postsurgical abdominal keloid scar after undergoing left colectomy for colon adenocarcinoma. Four months later, after treatment with low-dose enalapril (10 mg, once a day) for mild arterial hypertension, her keloid scar rapidly improved and she eventually made a complete recovery. second case involved a 70-year-old female with diabetes who was affected by a long-standing postsurgical abdominal keloid scar of 2 years' duration. She was intentionally treated with the same low dose of enalapril, and, after 6 months of therapy, the bad scar showed marked improvement. We conducted an exhaustive search of the literature pertaining to the wound healing process, specifically to determine whether angiotensin-converting enzyme (ACE) inhibitors have a healing effect on wounds. ACE inhibitors are known to induce reduction of left ventricular collagen content and to attenuate remodeling during the postinfarctual period (thus improving ventricular function), and they have been shown to exert a pulmonary antifibrotic effect. After conducting this literature search, it became apparent that no data on cutaneous scars and ACE inhibitors are available. During the posttraumatic or postoperative stage, it is useful to achieve the best possible aesthetic results and to decrease the risk of a disfiguring keloid scar, thereby avoiding revision surgery; to this purpose, an early treatment with a low dose of enalapril is a possible solution, even if further confirmatory observations are needed.
肥厚性瘢痕和瘢痕疙瘩是易患个体中出现的两种皮肤过度瘢痕化形式。患者之间的愈合过程差异很大,瘢痕演变不良的风险不可预测。瘢痕疙瘩会形成毁容性瘢痕,伴有红斑、疼痛或瘙痒,或活动范围受限,是发病的主要原因。本研究的第一作者有一个偶然发现,她54岁,因结肠腺癌接受左半结肠切除术后,腹部出现了一个红斑且疼痛的术后瘢痕疙瘩。四个月后,在用低剂量依那普利(10毫克,每日一次)治疗轻度动脉高血压后,她的瘢痕疙瘩迅速改善,最终完全康复。第二例是一位70岁的糖尿病女性,她有一个长达两年的术后腹部瘢痕疙瘩。她接受了相同低剂量的依那普利治疗,治疗6个月后,不良瘢痕有明显改善。我们对与伤口愈合过程相关的文献进行了详尽检索,特别是确定血管紧张素转换酶(ACE)抑制剂是否对伤口有愈合作用。已知ACE抑制剂可减少左心室胶原含量,并在心肌梗死后减轻重塑(从而改善心室功能),并且已证明它们具有肺部抗纤维化作用。在进行文献检索后,很明显没有关于皮肤瘢痕和ACE抑制剂的数据。在创伤后或术后阶段,实现尽可能好的美学效果并降低毁容性瘢痕疙瘩的风险,从而避免修复手术是很有用的;为此,即使需要进一步的证实性观察,早期使用低剂量依那普利治疗也是一种可能的解决方案。